123 related articles for article (PubMed ID: 12684096)
41. Angiotensin-converting enzyme and angiotensin II receptor subtype 1 inhibitors restitute hypertensive internal anal sphincter in the spontaneously hypertensive rats.
De Godoy MA; Rattan S
J Pharmacol Exp Ther; 2006 Aug; 318(2):725-34. PubMed ID: 16648368
[TBL] [Abstract][Full Text] [Related]
42. The effects of angiotensin II receptor blockade with losartan on systemic blood pressure and renal and extrarenal prostaglandin synthesis in women with essential hypertension.
Smith MC; Barrows S; Meibohm A; Shahinfar S; Simpson RL; Weigel K; Dunn MJ
Am J Hypertens; 1995 Dec; 8(12 Pt 1):1177-83. PubMed ID: 8998251
[TBL] [Abstract][Full Text] [Related]
43. Aminopeptidase A, which generates one of the main effector peptides of the brain renin-angiotensin system, angiotensin III, has a key role in central control of arterial blood pressure.
Reaux A; Iturrioz X; Vazeux G; Fournie-Zaluski MC; David C; Roques BP; Corvol P; Llorens-Cortes C
Biochem Soc Trans; 2000; 28(4):435-40. PubMed ID: 10961935
[TBL] [Abstract][Full Text] [Related]
44. Synthesis and antihypertensive activity of pyrimidin-4(3H)-one derivatives as losartan analogue for new angiotensin II receptor type 1 (AT1) antagonists.
Kim TW; Yoo BW; Lee JK; Kim JH; Lee KT; Chi YH; Lee JY
Bioorg Med Chem Lett; 2012 Feb; 22(4):1649-54. PubMed ID: 22264484
[TBL] [Abstract][Full Text] [Related]
45. Pharmacological properties of angiotensin II receptor antagonists.
Timmermans PB
Can J Cardiol; 1999 Nov; 15 Suppl F():26F-8F. PubMed ID: 10579749
[TBL] [Abstract][Full Text] [Related]
46. Contribution of the renin-angiotensin and kallikrein-kinin systems to short-term variability of blood pressure in two-kidney, one-clip hypertensive rats.
Ponchon P; Elghozi JL
Eur J Pharmacol; 1996 Feb; 297(1-2):61-70. PubMed ID: 8851167
[TBL] [Abstract][Full Text] [Related]
47. Effects of the AT1 antagonist HR 720 in comparison to losartan on stimulated sympathetic outflow, blood pressure, and heart rate in pithed spontaneously hypertensive rats.
Häuser W; Dendorfer A; Nguyen T; Dominiak P
Kidney Blood Press Res; 1998; 21(1):29-35. PubMed ID: 9661134
[TBL] [Abstract][Full Text] [Related]
48. Hypotensive effect of angiotensin II after AT1-receptor blockade with losartan.
Matys T; Pawlak R; Kucharewicz I; Chabielska E; Buczko W
J Physiol Pharmacol; 2000 Mar; 51(1):161-6. PubMed ID: 10768859
[TBL] [Abstract][Full Text] [Related]
49. Chronic hypotensive effects of losartan are not dependent on the actions of angiotensin II at AT 2 receptors.
Collister JP; Soucheray SL; Osborn JW
J Cardiovasc Pharmacol; 2002 Jan; 39(1):107-16. PubMed ID: 11743233
[TBL] [Abstract][Full Text] [Related]
50. Design, synthesis and antihypertensive evaluation of novel codrugs with combined angiotensin type 1 receptor antagonism and neprilysin inhibition.
Mascarello A; Azevedo H; Ferreira Junior MA; Ishikawa EE; Guimarães CRW
Eur J Pharm Sci; 2021 Apr; 159():105731. PubMed ID: 33493668
[TBL] [Abstract][Full Text] [Related]
51. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin.
Morsing P; Adler G; Brandt-Eliasson U; Karp L; Ohlson K; Renberg L; Sjöquist PO; Abrahamsson T
Hypertension; 1999 Jun; 33(6):1406-13. PubMed ID: 10373224
[TBL] [Abstract][Full Text] [Related]
52. A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists.
Vauquelin G; Morsing P; Fierens FL; De Backer JP; Vanderheyden PM
Biochem Pharmacol; 2001 Feb; 61(3):277-84. PubMed ID: 11172731
[TBL] [Abstract][Full Text] [Related]
53. Comparative antihypertensive activities of losartan and HM70186 in rats with hepatic dysfunction.
Choi JH; Shin S; Park D; Jeon JH; Choi BH; Jang MJ; Joo SS; Oh KW; Hong JT; Suh KH; Kim YB
Arch Pharm Res; 2009 Jul; 32(7):1005-11. PubMed ID: 19641881
[TBL] [Abstract][Full Text] [Related]
54. Novel dual action AT1 and ETA receptor antagonists reduce blood pressure in experimental hypertension.
Kowala MC; Murugesan N; Tellew J; Carlson K; Monshizadegan H; Ryan C; Gu Z; Kane B; Fadnis L; Baska RA; Beyer S; Arthur S; Dickinson K; Zhang D; Perrone M; Ferrer P; Giancarli M; Baumann J; Bird E; Panchal B; Yang Y; Trippodo N; Barrish J; Macor JE
J Pharmacol Exp Ther; 2004 Apr; 309(1):275-84. PubMed ID: 14718594
[TBL] [Abstract][Full Text] [Related]
55. Angiotensin II receptor antagonists: the prototype losartan.
Schaefer KL; Porter JA
Ann Pharmacother; 1996 Jun; 30(6):625-36. PubMed ID: 8792950
[TBL] [Abstract][Full Text] [Related]
56. Structural insight on the activity of type 1 angiotensin II peptide antagonists using MD simulations.
Preto MA; Melo A; Rodrigues LM; Maia HL; Ramos MJ
J Phys Chem B; 2008 Oct; 112(43):13620-8. PubMed ID: 18834172
[TBL] [Abstract][Full Text] [Related]
57. Losartan suppresses the kainate-induced changes of angiotensin AT
Atanasova D; Tchekalarova J; Ivanova N; Nenchovska Z; Pavlova E; Atanassova N; Lazarov N
Life Sci; 2018 Jan; 193():40-46. PubMed ID: 29223539
[TBL] [Abstract][Full Text] [Related]
58. AT1 receptors in the RVLM mediate pressor responses to emotional stress in rabbits.
Mayorov DN; Head GA
Hypertension; 2003 May; 41(5):1168-73. PubMed ID: 12654708
[TBL] [Abstract][Full Text] [Related]
59. The pharmacologic profile of 606A, a novel angiotensin II receptor antagonist.
Hashimoto Y; Harada Y; Narita H; Naito K; Murata S
J Cardiovasc Pharmacol; 1997 Feb; 29(2):284-90. PubMed ID: 9057080
[TBL] [Abstract][Full Text] [Related]
60. Synthesis and biological evaluation of novel potent angiotensin II receptor antagonists with anti-hypertension effect.
Nie YY; Da YJ; Zheng H; Yang XX; Jia L; Wen CH; Liang LS; Tian J; Chen ZL
Bioorg Med Chem; 2012 Apr; 20(8):2747-61. PubMed ID: 22410249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
